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ABSTRACT 
Tuberculosis is a disease which continues to be a major cause of morbidity and mortality in the 
third world. It has also resurged in first world countries linked to the Human Immunodeficiency 
Virus epidemic. Added to this is the increasing prevalence of multidrug-resistant tuberculosis, 
related primarily to erratic therapy. When multidrug-resistant isolates are found in association 
with the acquired immunodeficiency syndrome, a high case-fatality rate is seen. This formidable 
combination of diseases has caused great concern, and has resulted in renewed interest in the 
mechanisms of mycobacterial drug resistance. 
Streptomycin is one of the oldest and best studied antimicrobial agents; the ribosome being an 
important target of streptomycin action, if not the most important target. Streptomycin exerts it's 
therapeutic action via binding to the smaller subunit of the ribosome (30S). The molecules 
involved in the site of streptomycin binding and action are the 16S rRNA and a number of 
ribosomal proteins, particularly protein S12. The 16S RNA forms the backbone of the structure of 
the 30S subunit, with a number of regions, separated by several hundreds of bases, all 
implicated in binding to streptomycin. One region, in particular, has been shown to be involved in 
this interaction. This is the 915 region which we investigated in streptomycin resistant 
Mycobacterium tuberculosis isolates. 
A 913 A-G mutation was identified in 3 of the 41 multidrug-resistant M. tuberculosis isolates 
investigated using the PCR based amplification refractory mutation system (ARMS) to screen the 
isolates for the presence of either A or G at the 913 position. 
Twenty-five of the isolates were sequenced, either after cloning the region into a vector, or 
directly from PCR generated DNA fragments. This was done to determine whether any other 
mutations, which might affect the streptomycin binding, were present in 915 region, as well as to 
confirm the ARMS data. 
The ARMS method of point mutation detection offers the possibility of revolutionising drug 
sensitivity testing where chromosomal mutations occur in genes encoding proteins or rRNA that 
bind antimicrobial drugs. 
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CHAPTER 1 
LITERATURE REVIEW 
1.1 INTRODUCTION 
The history of tuberculosis and streptomycin is presented briefly as a background to this 
dissertation. Streptomycin resistance of microorganisms, and the mechanisms of resistance, with 
particular reference to the streptomycin-ribosome interaction are covered, and the data 
concerning the recent strides made in uncovering these mechanisms in Mycobacterium 
tuberculosis, are presented. 
1.2 TUBERCULOSIS 
1.2.1 HISTORY 
Tuberculosis is a disease of great antiquity. It has been a scourge of immense proportions which 
continues until the present to be a major cause of morbidity and mortality, particularly in the third 
world. In South Africa the reported incidence of tuberculosis peaked in 1963 with 372 cases per 
100 000 of the total population. In 1990 this incidence was 237 cases per 100 000. The estimated 
total number of persons infected with M. tuberculosis was 6 to 1 O million in South Africa in 1990 
(>Neyer & Kleeberg, 1992). One-third of the world's population is infected with M. tuberculosis 
(Ehlers, 1993). 
Ancient descriptions of the disease are recordered as far back as 5000 BC. An accurate clinical 
description was made by Hippocrates in approximately 460-370 BC (Burke, 1955). Knowledge of 
the disease was furthered by the description of tubercles by Sylvius in 1679, as well as by the 
post mortem studies of Laennec in 1819, in which he recognized the unitary nature of the 
disparate symptoms and signs of the disease. In 1865 Villemin demonstrated the infectious 
nature of the disease by inoculating rabbits with material taken from human patients. This was 
followed by the discovery of the aetiology of tuberculosis, the tubercle bacillus, by Dr Robert 
Koch who announced his discovery in a paper read in Berlin on 24 March, 1882 (Koch, 1932). It 
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was Koch too, who prepared tuberculin, and demonstrated the pathogenicity of the bacillus 
experimentally. 
It is estimated that a quarter of all adult deaths in Europe was caused by tuberculosis during the 
seventeenth and eighteenth centuries (Des Prez & Heim, 1990). Yet the treatment developed 
then, consisting of rest and fresh air, remained in practice until the middle of this century. This 
was to change with the discovery of antitubercular drugs. In 1942 Feldman et al showed that 
sulphones exerted a therapeutic effect in experimentally produced tuberculosis, followed in 1943 
by Waksman's discovery of streptomycin (Schatz et al, 1944) which heralded the 'streptomycin 
era' (1947-1952). Thereafter the discovery of para-aminosalicylic acid (PAS) and 
thiosemicarbazones in 1946, isoniazid in 1951, rifampicin in 1970, and pyrazinamide 
transformed therapy. This changed the prognosis of the disease from a very poor one 
(approximately 50% of patients died within two years, while only 25% recovered), to one one 
which was eminently curable (98-99% cure in previously untreated pulmonary tuberculosis ). 
1.2.2 MICROBIOLOGY 
1.2.2.1 CLASSIFICATION 
M. tuberculosis is a species of the family Mycobacteriaceae, order Actinomycetales. M. 
tuberculosis and M. bovis are both included by the description 'tubercle bacillus', but M. bovis as 
a cause of disease in humans is now rare. 
M. tuberculosis is an aerobic, non-motile, non-spore forming bacteria which has a high content 
of waxy materials in the cell wall. This waxy cell wall results in the characteristic acid fastness 
seen on staining with carbol fuchsin in the Ziehl-Neelsen stain. 
Mycobacteria are widespread in nature ranging from soil-dwelling saprophytes to pathogens of 
humans and animals. M. tuberculosis falls into this latter group, being an obligate pathogen of 
humans, and mammals found in close proximity to humans, e.g. dogs. 
M. tuberculosis has a slow growth rate with a generation time of between 15 and 20 hours, with 
visible colonial growth taking at least 3 weeks and usually 4 to 6 weeks on solid media. 
Using differences in growth rate and pigmentation, the genus Mycobacterium has been divided 
into four groups: group I, the photochromogens (slow growing); group II, the scotochromogens 
(slow growing); group Ill, the non-photochromogens (slow growing); and group IV, the rapid 
growers (Sommers & Good, 1985). This classification was first developed by Runyon in 1959 as 
a classification of 'anonymous' or non-tuberculous mycobacteria; mycobacterial isolates which 
were recognised as displaying unusual characteristics that differed from the tubercle bacillus. 
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The identification of mycobacteria by species is now preferred. This requires a variety of 
specialised and complex tests to be done; enzyme assays, growth charateristics, morphology 
and drug susceptibility. In an effort to improve on these methods other approaches have been 
suggested, including immunological methods and DNA composition (Bradley, 1973). Recently 
the nucleic acid sequence of 16S and 23S rRNA has received much attention as a useful way of 
establishing phylogenetic relationships within the genus Mycobacterium (Rogall et al, 1990; 
Edwards et al, 1989; Liesack et al, 1990; Liesack et al, 1991; Suzuki et al, 1988; Estrada-G et al, 
1989; reviewed by Olsen, 1993). A phylogenetic tree was constructed using the 16S rRNA 
(Rogall et al, 1990) and is presented in figure 1.1. Of note, the sequences for M. tuberculosis, M. 
tuberculosis H37, M. bovis and M. bovis BCG were identical, and are therefore represented in 
the tree by a single branch . 
.----- M. fortuitum 
~----< 
,___ __ M. che/onae 
~-- M. smegmatis 
'------4... ___ M. f/avescens 
.-------- M. simiae 
,----- M. terrae 
RAPID GROWERS 
SLOW GROWERS 
M. nonchromogenicum 
.__ ____ 1------------------ M. xenopi 
~----- M. gordonae 
M. tuberculosis 
M. marinum 
.------ M. scrofulaceum 
---- M. gastri IM. kansii 
M. paratubercu/osis 
M. avium 
FIGURE 1.1: Phylogenetic tree showing relationships of species belonging to the genus 
Mycobacterium. After Rogall et al (1990). Bar = 1 O nucleotide positions. 
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1.2.3 LABORATORY DIAGNOSIS 
1.2.3.1 MICROSCOPY 
The initial mode of mycobacterial identification is microscopic examination of a specimen after 
staining. Gram staining is not useful as the organisms demonstrate weak Gram-positive staining 
or remain colourless. Mycobacteria have the unusual staining characteristic known as acid-
fastness. This has been attributed to the high mycolic acid content of the cell wall (Minniken, 
1982; Ehlers, 1993). The organisms, when stained by carbol fuchsin, are resistant to 
decolourisation by acid-alcohol. This property is seen when the Ziehl-Neelsen and Kinyoun 
staining method is used. Fluorochrome staining with phenolic auramine or auramine-rhodamine 
also rely on the acid-fastness for detection of mycobacteria. Microscopy is not sensitive, requiring 
approximately 5 000 to 10 000 organisms per ml of sputum for detection (Hobby et al, 1973). 
1.2.3.2 CULTURE 
Laboratory culture is a far more sensitive method of detection, being able to detect as few as 1 O 
organisms per inoculum (Hobby et al, 1973). Culture of sputum requires a decontamination 
procedure, while specimens taken from "sterile" sites under aseptic conditions can be inoculated 
directly onto/into culture medium, Lowenstein and Jensen, a solid egg based medium, and 
Kirschner, a liquid medium. The major problem is that these culture methods may take up to six 
weeks to become positive, with sensitivity testing requiring a further 3-6 weeks. 
Newer culture methods e.g. the Bactec system, are based on the measurement of a growth index 
which measures microbial growth by detecting the conversion of a radiolabelled carbon source to 
14C02, This system is capable of detecting organisms very much quicker (2-6 days). 
1.2.3.3 MOLECULAR TECHNIQUES 
Molecular methods offer the possibility of even quicker detection and identification. DNA probes 
use labelled DNA to hybridise to specific DNA or RNA sequences of extracted nucleic acids from 
cultured mycobacteria. A limited number of species can be identified in this way. However, direct 
detection of mycobacteria in clinical specimens is approximately 1 oo times poorer than culture, 
and false positives occur (McFadden et al, 1990). DNA fingerprinting, in which the extracted 
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DNA is restriction enzyme digested and probed with labelled DNA according to the Southern blot 
procedure, is useful for identifying strains. High performance liquid chromatography (HPLC) of 
the mycolic acids from a culture of the organisms is able to identify a wide range of species 
based on the chromatographic pattern produced (Desmond, 1992). The polymerase chain 
reaction (Saiki et al, 1985) offers the possibility of rapid detection (De Wit et al, 1990; Lombard et 
al, 1994) and identification. It may even be used in drug susceptibility testing (Douglass & Steyn, 
1993; Honore & Cole, 1994). 
1.2.4 THERAPY 
A variety of treatment regimens have been used since the 1950s. They all have in common the 
use of multiple drugs in combination, in an effort to avoid the appearance of drug resistance and 
to kill the mycobacterial population quickly. In addition variations in the treatment period, 
supervised drug administration, intermittent treatment and number and type of drug have been 
assessed. 
A standard regimen in South Africa would be to use isoniazid, rifampicin and pyrazinamide for 6 
months, with ethambutol added in areas known to have a high incidence of isoniazid resistance 
0fveyer & Kleeberg, 1992). Streptomycin, which was used until recently, has been substituted by 
ethambutol without a loss of treatment potency, thereby converting the regimen to oral drugs only 
(Snider et al, 1986). 
Spontaneous resistance occurs at a rate between 1x10-6 and 1x10-8 per generation. This is 
important if only one drug is used, and a large enough number of organisms are present. This 
situation is found in pulmonary cavitatory disease when there may be >109 organisms present. 
Erratic treatment is known to select drug resistant organisms (Mitchison, 1984). 
1.2.5 EPIDEMIOLOGY 
The infection is usually spread by airborne droplets, and the incidence of infection is related to 
overcrowded conditions and poor inherent resistance of individuals. First world countries such as 
the USA and Britain, have seen a steady decline in the incidence of tuberculosis since the 
1950's. In contrast in third world countries the incidence of tuberculosis has remained 
unacceptably high (Comstock, 1982). This includes South Africa, and in particular the Western 
Cape, which has a disproportionately high incidence of tuberculosis; the 1990 reported incidence 
for "Coloureds" was 626 per 100 000 0fveyer & Kleeberg, 1992). With the spread of human 
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immunodeficiency virus (HIV) infections worldwide, however, there has been an increasing 
incidence of tuberculosis in first world countries (Sumartojo, 1993), and an increased incidence of 
drug resistant cases (Hurley and Andrew, 1993; Grandes et al, 1993; ldigbe et al, 1992). This 
has resulted in a renewed interest in tuberculosis (Nardell, 1993; Weiss, 1992), and the molecular 
mechanisms of resistance (Ahern, 1993; Beardsley, 1992). 
1.3 STREPTOMYCIN 
1.3.1 HISTORY 
In 1944 Waksman announced the discovery of streptomycin (Schatz et al, 1944). It's efficacy in 
experimentally produced tuberculosis was demonstrated (Feldman et al, 1945; Youmans & 
Mccarter, 1945), and it was used in a clinical trial of therapy in 24 patients with pulmonary 
tuberculosis (Hinshaw et al, 1945). This was soon followed by a larger controlled trial (the first 
controlled randomised clinical trial of a drug!) in which the beneficial effects of streptomycin were 
clearly shown (British Medical Research Council, 1948). These trials also revealed the presence 
of bacterial drug resistance and drug toxicity. This resistance to therapy using streptomycin was 
seen as the major drawback to it's clinical usefulness. However, experimentation with para-
aminosalicylate (PAS) had suggested it's efficacy, and subsequently the combination of the two 
drugs was compared to using streptomycin only (British Medical Research Council, 1949; British 
Medical Research Council, 1950). The most remarkable finding was that the incidence of 
streptomycin-resistant organisms was 70% in the streptomycin only group, as compared with 9% 
in the group receiving both drugs. These trials established a place for the use of combination 
therapy in the treatment of tuberculosis. 
Streptomycin remained one of the mainstays of the treatment of tuberculosis until recent times 
when alternative less toxic, and easily administered drugs, have become preferred. 
1.3.2 STRUCTURE 
Streptomycin, derived from Streptomyces griseus, is an aminoglycoside i.e. it contains two 
aminosugars linked by glycosidic bonds to an aminocyclitol ring (streptidine). The structure can 
be seen in Figure 1.2. 
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streptidine 
} L-glucosamine 
FIGURE 1.2 The atomic structure of streptomycin, from Lietman, 1990. 
1.3.3 MECHANISM OF ACTION AND RESISTANCE 
1.3.3.1 INTRODUCTION 
The mechanism of action of streptomycin and resistance are discussed together because of the 
intimate way research into the one subject is related to the other. 
Organisms can be resistant to aminoglycosides by one, or combinations, of three possible 
mechanisms: 
1.) by ineffective uptake of the drug, 
2.) by enzymatic modification the drug, or; 
3.) by reduced affinity between drug and ribosome. 
1.3.3.2 TRANSPORT ACROSS THE CELL WALL AND MEMBRANE 
The precise nature of the transport of streptomycin (and other aminoglycosides) across the cell 
wall and membrane remains a subject for debate (Hancock, 1981). There is evidence for an 
energy dependant mechanism of transport involving a carrier molecule (Bryan & van den Elzen, 
1976; Nichols, 1987), but not stringent proof for the existence of a carrier (Hancock, 1981). 
Resistance in bacteria, caused by ineffective transport, is thought to be due to the inability of the 
cell to maintain the required electromotive potential (Hancock, 1981). Mutations involving many 
different sites, including ribosomal mutations (e.g. the S12 mutation), have been shown to affect 
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aminoglycoside transport (Hancock, 1981). There is speculation that this mechanism of 
resistance may be present in mycobacteria (Honore & Cole, 1994), but, as yet there is no proof. 
1.3.3.3 ENZVMATIC MODIFICATION OF AMINOGLYCOSIDES 
In many bacteria, aminoglycoside resistance is due to the production of aminoglycoside 
modifying enzymes (Edson & Terrell, 1991). These are usually coded for by genes found on 
plasmids or transposable elements. Although certain of the Mycobacteria have been found to 
harbour such elements and aminoglycoside modifying activity has been detected in fast growing 
species (Martin et al, 1990), they have not been found in M. tuberculosis (Martin et al, 1990). 
This mechanism will therefore not be discussed further. 
1.3.3.4 THE STREPTOMYCIN-RIBOSOME INTERACTION 
Streptomycin inhibits protein synthesis by interaction with the ribosome (Spotts & Stanier, 1961), 
specifically the 30s subunit (Chang & Flaks, 1972; Schreiner & Nierhaus, 1973). The effect of 
streptomycin at the ribosome is to cause an increased error of translation, and stimulating the 
breakdown of polysomes to monosomes (Modolell & Davis, 1970). This prevents chain 
elongation and prevents effective initiation of translation. 
Hancock (1981) argued that inhibition of protein synthesis may not be the lethal event. According 
to his argument the action of streptomycin is not confined to only one critical target, but may act 
at two targets. He suggests that one of five other possibilities occurs as the lethal event; cell wall 
destruction, cytoplasmic membrane puncture, a lethal hit on an essential gene, cross-linking or 
double strand breaks in the DNA or disruption of the DNA-membrane attachment site. 
Davis et al (1986) proposed that the membrane is damaged by the incorporation of misread 
proteins which create abnormal channels through which streptomycin enters irreversibly at an 
increased rate. 
1.3.3.4.1 THE 30S PROTEINS 
Streptomycin binds the 30S subunit of the ribosome of E. coli at a single site (Chang & Flaks, 
1972; Schreiner & Nierhaus, 1973; Grise-Miron & Brakier-Gingras, 1982). Early work pointed 
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toward the ribosomal proteins (see figure 1.2) as the important mediators of the streptomycin-
ribosomal interaction (Ozaki et al, 1969; Birge & Kurland, 1969; Schreiner & Nierhaus, 1973). 
Protein S12 was shown to be necessary for the action of streptomycin on the ribosome; the 
absence of S12 or the presence of a mutation in this protein caused the 30S subunit to bind 
streptomycin weakly when compared to subunits containing wild-type S12 (Ozaki et al, 1969). 
Birge and Kurland (1969) used ribosomes from streptomycin dependent E. coli (these require 
streptomycin for maximal polypheylalanine synthesis when primed by poly(U) mRNA). Using 
reconstitution experiments they showed that a single 30S subunit protein was altered in the 
streptomycin dependent ribosomes; the same protein which Ozaki et al (1969) had identified in 
streptomycin resistant ribosomes, namely S12. 
Proteins S4 and SS were postulated to be part of a single binding site of dihydrostreptomycin on 
the 30S subunit (Schreiner & Nierhaus, 1973). They discovered two types of binding; one to the 
30S subunit which predominated, was protein dependent, specifically involving proteins S4 and 
SS and is at one site only. The second type of binding is mentioned only briefly; that to the 16S 
and 23S RNA and the SOS subunit, which was a far weaker binding. It is interesting to note that 
they did not demonstrate binding to S 12, although it was specifically tested for. 
Further S12 mutations were discovered in streptomycin resistant ribosomes of many species 
(Galili et al, 1989; Salles et al, 1992). Two regions may be altered; position 42(Lys) and the 
region from positions 85 to 91 (Funatsu & Wittmann, 1972; Galili et al, 1989; Salles et al, 1992). 
Affinity labeling experiments using a streptomycin analogue and E. coli ribosomes (Pangs & 
Erdmann, 1973; Pangs et al, 1974), showed the analogue to react irreversibly and specifically to 
the 70S ribosome. They were furthermore able to show that the analogue was attached to the 
30S subunit, probably S3 and S4. They did not detect any reaction to the rRNA. 
S4 and S5 ram (ribosomal ambiguity) mutations were shown to enhance streptomycin binding 
and therefore increase the sensitivity of ribosomes to streptomycin (Bock et al, 1979). The 
introduction of ram mutations into ribosomes containing a S12 mutation, results in the reversal of 
the restriction of translational ambiguity caused by the S12 mutation. i.e. they have opposite 
effects (Biswas & Gorini, 1972). 
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FIGURE 1.2: The 30S subunit of the ribosome as viewed from the interface betwen the two 
subunits, showing the relative positions of proteins and RNA loops involved in streptomycin 
binding. The central shaded area indicates the position of the S' terminal, beneath which lies the 
900 helix. (from Leclerc et al (1991)" 
M. tuberculosis ribosomal proteins from streptomycin sensitive and resistant isolates were 
compared by Medow et al (1987). They detected two additional proteins in the 30S subunit; 28 
proteins as compared to 26 in sensitive ribosomes, and an altered mobility of the protein L34 on 
two dimensional electrophoretic gels. It is interesting to note that the total number and molecular 
weights of ribosomal proteins was found to be different in different species, e.g. E. coli and M. 
tuberculosis. 
Very recently, a mutation in protein S 12 from streptomycin resistant M. tuberculosis isolates has 
been discovered (Finken et al, 1993). This is present at codon 88 of the rpsL gene. A mutation 
was also found in the rpsL gene at codon 88(Lys to Arg) in a streptomycin resistant M. 
tuberculosis isolate which had a simultaneous 913 A~G mutation in the 16S rRNA gene (Meier 
et al, 1994). 
Honore and Cole (1994) reported S12 mutations in two out of six streptomycin resistant M. 
tuberculosis isolates. They showed that two of the six isolates investigated contained mutations 
at position 43(Lys to Arg) in the S 12 (rpsL) gene. Two of the isolates contained 912 mutations of 
the 16S rRNA (rrs) gene, and in two no mutations were found. 
A paper has also been presented on this topic (Morris et al, 1993), the abstract of which I have 
read. Five streptomycin resistant M. tuberculosis isolates were reported to contain an identical 
mutation (A~G), at codon 43 of the gene encoding protein S12, while the parental strains and 
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two further streptomycin resistant M. tuberculosis isolates were not mutated. This work has not 
yet been published in full. 
1.3.3.4.2 THE 165 rRNA 
Evidence which supported direct binding of streptomycin to naked 16S rRNA appeared after it 
had been established that protein-streptomycin binding was important. (Biswas & Gorini, 1972; 
Garvin et al, 1974; Melanc;on et al, 1984). Gorini's group used radiolabeled streptomycin and 
dihydrostreptomycin in equilibrium dialysis experiments to show that the drug binds stably to the 
16S rRNA, and not to the 23S rRNA (Biswas & Gorini, 1972; Garvin et al, 1974). 
1.3.3.4.2.1 CROSS-LINKING EXPERIMENTS 
Melanc;on et al (1984) used the bifunctional cross-linking agent phenyldiglyoxal to determine 
precisely the site at which streptomycin binds. The streptomycin-30S complex was allowed to 
form after which phenyldiglyoxal was added. This caused covalent cross-linking to occur by 
reacting with the guanosine of ssRNA and guanidine groups of arginine residues in the proteins. 
The potential for cross-linking streptomycin through it's guanidine residues to the guanosine of 
ssRNA, was recognised and used for these experiments. They showed that streptomycin bound 
reversibly to the 30S subunit, and that the binding was tighter to the 30S subunit of a 
streptomycin-sensitive E. coli than to the 30S subunit of a streptomycin-resistant E. coli. They 
showed that streptomycin binds a specific site by succesfully abolishing cross-linking in the 
presence of bluensomycin, an agent which competes for the streptomycin binding site (Chang & 
Flaks, 1972). This excluded the possibility that phenyldiglyoxal might have caused cross-linking 
at indiscriminate sites on the 30S subunit. The cross linked 30S subunit was then incubated 
either with proteinase K or RNAse before precipitation and counting the radioactivity of the 
precipitate. This showed that the streptomycin was binding mainly to the RNA (75%), and to a 
lesser extent to ribosomal proteins. Protein electrophoresis of extracted 30S ribosomal proteins 
on 1 dimensional and 2 dimensional polyacrylamide gels, identified the bound proteins to be S1, 
SS, S11 and S13. Interestingly S12 did not show cross-linking to streptomycin suggesting that it 
is not located in the streptomycin binding site. Yet it is known to be involved in the ribosomal 
response to streptomycin (Ozaki et al, 1969; Birge & Kurland, 1969). This, together with results 
of experiments reported by the same group (Brakier-Gingras et al, 197 4), in which it was shown 
that streptomycin induces conformational changes in streptomycin sensitive but not in 
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streptomycin-resistant ribosomes, led the authors to postulate that the binding of streptomycin 
occurs in a two-step reaction. An initial interaction would be followed by a conformational change 
in which the association with antibiotic is tightened and protein synthesis is interrupted. Thus 
protein S12 would occupy a site close to the streptomycin binding site which controls the ability of 
the ribosome to undergo the conformational change. 
Gravel et al (1987) then went on to localise the site of cross-linking to the 16S RNA. Tritiated 
streptomycin was cross-linked to the 30S subunit or to the 70S ribosome of E. coli using nitrogen 
mustard. This was then hybridized to restriction fragments of the 16S RNA gene. By using a 
variety of restriction enzymes the region of the gene to which the labeled RNA hybridized was 
localized. Two regions were identified, one corresponding to positions 892-917, and the other to 
positions 1394-1415. 
1.4.4.3.2 RNA FOOTPRINTING 
RNA footprinting done by Moazed and Noller (1987), indicated direct binding of the antibiotic to 
the 16S rRNA. In these experiments ribosomes from E. coli were incubated with streptomycin 
prior to chemical attack of covalent bonds within bases by dimethylsulphate (DMS). The RNA 
was then subject to primer extension using reverse transcriptase. Where the bases are damaged, 
a termination occurs; where the bases are protected readthrough occurs. In this way bases 
protected by the binding of the antibiotic can be identified. They showed that three adenosines at 
positions 913, 914 and 915 are strongly protected by streptomycin and that there is weaker 
protection of bases U911 and C912 (see figures 1.3 and 1.4). The experiments were repeated 
with the 30S subunit alone. This showed additional weak protection of bases A909, A 1413, 
G1487 and G1494. Some of these sites (909, 1413 and 1487) are also protected by tRNA and by 
SOS RNA in a non-competitive manner (known as class Ill sites). Therefore, they suggested that 
these sites are not protected by directly binding streptomycin, but possibly because a 
conformational change is induced by the streptomycin binding, or due to the formation of a 
pocket when both ribosomal subunits are present, which can be blocked by the drug. 
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FIGURE 1.3: Secondary structure of the 16S rRNA highlighting the 530, 915 and 1440 loops. 
The 915 loop is central to the structural of the 16S rRNA. and it is at this point that movement is 
thought to occur during conformational changes (from Moazed and Noller, 1987). 
1.3.3.4.3 RIBOSOMAL RNA MUTATIONS 
1.3.3.4.3.1 POSITION 912 
Montandon et al (1985) reported the finding of a 912 C-+ T base change in the chloroplast 16S 
rRNA gene of two streptomycin resistant Euglena gracilis isolates. To support the postulate of 
linkage between the mutation and streptomycin resistance, they argued that this is a highly 
conserved position across phylogenies, and an invariant position in eubacteria and chloroplast 
DNA. Furthermore, the S12 gene in these resistant chloroplasts was unchanged, and that 
archaebacteria, which are resistant to streptomycin, contain the same base at the analogous 
position. Later the same position was found to be mutated (912 C-+A) in the 16S rRNA gene of 
streptomycin resistant Nicotiana tabacum chloroplasts (Etzold et al, 1987). 
Frattali et al (1990) investigated the effect of introducing four different mutations into position 
912 of E. coli ribosomes. They introduced the mutations (912 C-+U, 912 C-+G, 912 C-+A and a 
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deletion at 912) into the m18 operon of the multicopy plasmid, pKK3535, which was used to 
transform E. coli. They found that two of the mutations (912 c~u and 912 c~G) conferred a 
low level of resistance to streptomycin, and that after selection in progressively higher 
concentrations of streptomycin, a high level of resistance was obtained in cells containing the 
912 c~u mutation. However after removal of the plasmid the cells retained a higher level of 
resistance than the original wild type strain, even though the 912 c~u mutation was not present 
due to a homologous recombination event in the chromosomal DNA. Retransformation of these 
cells to introduce the 912 c~u mutation again caused an enhanced resistance to streptomycin. 
They also introduced the 912 c~u mutation into ribosomes from three strains of E. coli which 
were streptomycin dependent by virtue of S12 protein mutations. These E. coli strains require the 
binding of streptomycin. The plasmid was lethal in one strain and caused ribosomes from two 
other strains to be non-functional; the explanation being that the mutation prevented the proper 
binding of streptomycin. 
Honore and Cole (1994) have reported 912 mutations in two streptomycin resistant M. 
tuberculosis isolates. They showed that two of the six isolates investigated contained 912 C~G 
or 912 C~A substitutions respectively. Two of the isolates contained S12 mutations at position 
43(Lys to Arg) and in two, no mutations were found in the S12 (rpsL) gene or in selected regions 
of the 16S rRNA (rrs) gene. 
1.3.3.4.3.2 POSITION 913 AND 915 
Leclerc et al (1991) succesfully introduced two mutations, 913 A~G and 915 A~G. into 16S 
rRNA of ribosomes in E coli (see figure 1.4). Using these ribosomes, as well as ribosomes 
containing a 912 u~c mutation, they investigated the streptomycin-ribosome interaction. 
Approximately 67% of ribosomes extracted from each E. coli clone contained the mutation, 
which had been introduced into the rmB operon of pKK3535. Ribosomes were assayed for 
misreading of a poly(U) messenger in the presence of streptomycin. They showed that the 
mutations restricted the misreading caused by streptomycin. The 913 A~G and 915 A~G 
mutations did not cause a decreased protein synthesis in the absence of streptomycin, but did 
restrict the inhibition of protein synthesis in the presence of streptomycin. Lastly, they showed 
that the mutant ribosomes had a decreased binding affinity for streptomycin. 
In this report we describe an A~G point mutation at position 913 in streptomycin resistant M. 
tuberculosis isolates (Douglass & Steyn, 1993). These results have recently been confirmed by 
Meier et al, (1994). 
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FIGURE 1.4: The 915 region of the 16S rRNA (from Leclerc et al, 1991 a). 
1.3.3.4.3.3 POSITION 13 AND 13+914 
Pinard et al, (1993) investigated the idea that the 5' proximal helix of the ribosome is involved in 
streptomycin binding by a conformational change to stabilize the binding of the drug (Leclerc & 
Gingras, 1991 ). Four mutations (13 u-A, 13U-c, 914 A-U and 914 A-G) were introduced, 
either individually or as double mutations ( 13 u-A and 914 A-U or 13U-C and 914 A-+G) into 
E. coli. None of the mutations affected the growth rate, but they all impaired the binding of 
streptomycin to the ribosome, and consequently protected the ribosomes against streptomycin 
induced misreading. However, the double mutations, which restore the capacity of position 13 to 
base pair with position 914, did not restore the binding of streptomycin. Therefore, the idea that a 
conformational change produces a novel helix which is essential for streptomycin binding, was 
not supported by their data. 
1.3.3.4.3.4 THE 530 LOOP 
An A-C mutation was introduced at position 523 of the 530 loop (see figure 1.3) of E.coli 
ribosomes (Melan<ton et al, 1988; Leclerc et al, 1991 b) in the same way as described above. The 
effect was to decrease streptomycin binding to the 30S subunit and restrict the misreading 
caused by streptomycin. 
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Meier et al (1994) found point mutations, 501 C-?U and 522 C-?U, in two streptomycin resistant 
M. tuberculosis isolates, while none of the 35 control isolates contained a mutation. 
1.3.3.4.4 INVOLVEMENT OF THE SOS SUBUNIT 
Melanc;:on et al (1992) investigated the effect of two mutatons (2661 G-?C and 2661 G-?U) on 
the binding of streptomycin, neomycin and gentamycin to ribosomes, and misreading of the 
ribosomes in the presence of the aminoglycosides. This was done using pKK3535 and E.coli. 
They found that although the mutations did protect the ribosomes against misreading, although 
neither affected the drug-ribosome binding. The effects of the 2661 mutations were similar to 
those obtained for L6 mutations (Ki.ihberger et al, 1979; Hummel et al, 1980), a SOS protein 
found in close proximity to the 2660 loop. They proposed that the 2660 loop is also part of the 
ribosomal site which controls the proofreading step. 
1.4 CONCLUSION AND AIMS OF THIS STUDY 
The ongoing prevalence of tuberculosis in our country and the world with the incumbent problem 
of resistance of the organism to effective drug therapy makes the study of the mechanisms of 
drug resistance in M. tuberculosis most important. 
Streptomycin is one of the oldest and best studied antimicrobial agents. The interaction of 
streptomycin with the cell is complex. I have sketched the major points of it's interaction with the 
ribosome, known to be one of the most important targets of it's action, if not the most important 
target. 
The level of understanding of the streptomycin-ribosomal interaction is well developed, but still 
not complete. The small subunit of the ribosome, particularly the 16S rRNA and protein S12 
have received much attention in E. coli. The importance of the 16S rRNA for streptomycin 
binding and action are well demonstrated at ribosomal level, with the 915 region structurally 
pivotal to all of the sites implicated in the streptomycin-ribosomal interaction. 
We investigated the possibility that a 16S rRNA mutation in the 915 region may be responsible 
for the resistant phenotype displayed by M. tuberculosis isolates. The M. tuberculosis 
chromomsome is known to contain only one set of of RNA genes as opposed to the seven sets 
carried by E. coli. A single point mutation which decreases streptomycin binding should, 
therefore, be immediately apparent at the phenotypic level. 
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CHAPTER 2 
MATERIALS 
2.1 PLASMID AND HOST CELLS 
pUC18, a lacZ' vector with ampicillin as the antibiotic marker (Yanisch-Perron et al, 1985), and E. 
coli LK111 cells, a derivative of K514, lacr, lac.2M15, lacv+ (Zabeau & Stanley, 1982), were 
provided by Professor Lafras Steyn, Department of Medical Microbiology, UCT Medical School, 
Observatory. A map of pUC18 is shown in appendix A. 
2.2 M. TUBERCULOSIS ISOLA TES 
Streptomycin resistant M. tuberculosis isolates were obtained from the mycobacterial laboratory, 
Groote Schuur Hospital, Observatory and the South African Institute of Medical Research, 
Orange street, Cape Town. DNA from two isolates was received from Ian Wiid, Department of 
Medical Biochemistry, Tygerberg Hospital, Tygerberg. 
2.3 ENZVMES, CHEMICALS, SOLUTIONS AND MEDIA 
All reagents and suppliers are listed below. 
2.3.1 ENZVMES AND KITS 
EcoRI 
Hindi II 
Proteinase K 
Sequenase 
Smal 
Taq polymerase 
Boehringer Mannheim 
Boehringer Mannheim 
Boehringer Mannheim 
United States Biochemicals 
Boehringer Mannheim 
Boehringer Mannheim 
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T 4 DNA ligase 
T7 Sequencing kit 
RNAse 
Uracil DNA Glycosylase 
2.3.2 CHEMICALS AND REAGENTS 
Acetic acid 
Acetone 
Acrylamide 
Agarose 
Ammonium Acetate 
Ampicillin 
Bis (N,N'-methylene bis acrylamide) 
Boric Acid 
Bromophenol blue 
Calcium chloride 
Caesium chloride 
Chloroform 
Chromatography paper 3mm 
Deoxynucleotide triphosphates 
Dimethyl formamide 
Dimethyl sulphoxide 
Ethylenediaminetetraacetic 
acid (EDTA) 
Ethidium bromide 
Ethanol 
Fixer (AMFIX) 
Formamide 
Glycerol 
Glycogen 
Hydrochloric acid 
8-Hydroxyquinolone 
IPTG (isopropyl-~-D-thiogalacto-
pyranoside) 
Boehringer Mannheim 
Pharmacia 
Sigma 
BRL 
BDH 
BDH 
BDH 
Promega Corp 
BDH 
Beechams 
Sigma 
Merck 
Sigma 
Merck 
Boehringer Mannheim 
Merck 
Whatman 
Boehringer Mannheim 
BDH 
Merck 
Boehringer Mannheim 
Merck 
BDH 
Maybaker 
BDH 
BDH 
Boehringer Mannheim 
BDH 
Merck 
Boehringer Mannheim 
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lsoamyl alcohol Merck 
lsopropanol BDH 
Lysozyme Boehringer Mannheim 
Lithium Chloride Sigma 
2-Mercaptoethanol Merck 
N-cetyl-N,N,N-trimethyl ammonium Sigma 
bromide (cetramide) 
Nonidet P40 Sigma 
Phenol BDH 
Potassium acetate Fluka 
35s-dCTP Amersham & Du Pont 
Sodium chloride Merck 
Sodium citrate BDH 
Sodium deoxycholate BDH 
Sodium dodecyl sulphate (SOS) Sigma 
Sodium hydroxide Saarchem 
Sterile distilled water BDH 
Sucrose BDH 
TEMED (N,N,N' ,N' ,-tetra methyl- Sigma 
ethylenediamine) 
Tris(hydroxymethyl)amino- Boehringer Mannheim 
methane (Tris) 
Triton X-100 BDH 
Tween 20 Sigma 
X-Gal (5-bromo-4-chlor- Boehringer Mannheim 
3-indolyl-~-D-galactopyranoside) 
X-ray film (curix) Agfa 
X-ray film developer (llford Phenisol) lsophoto 
2.3.3 MEDIA AND SOLUTIONS 
Luria agar and Luria broth were prepared by the media division of the Department of Medical 
Microbiology, University of Cape Town. These were stored at room temperature. The agar was 
melted in a microwave oven before being poured into petri dishes for use. 
Lowenstein Jensen slopes were prepared by the media division of the Department of Medical 
Microbiology, University of Cape Town. 
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Saturated phenol was prepared as described by Sambrook et al (1989) and stored frozen (-20°C) 
until use. 
Ampicillin (25 mg/ml) was stored at -20°C in aliquots and used at a final concentration of 
50ug/ml. 
1 O x NNB buffer: 162g Tris base 
27.5g boric acid 
9.3g Na2EDTA.2H20 
made up to 11 with sterile distilled water. 
50% acrylamide stock: 125g acrylamide 
12.5g bis 
made up to 250ml with sterile, distilled water, filtered, and stored in the 
dark at 4°C. 
2.3.4 SUPPLIERS 
Amersham 
BDH 
Boehringer Mannheim GmbH 
BRL 
Du Pont de Nemours & Co 
lsophoto 
Maybaker (SA) 
Merck 
Pharmacia 
Promega Corp 
Saarchem 
Sigma 
United States Biochemicals: 
Little Chalfont. Buckinghamshire, England. 
Poole, BH15 ITD, England. 
Biochemica, PO Box 310,120, 0-6800, Mannheim 31, 
West Germany. 
Cowley Mill Trading Estate. Longbride Way, Uxbridge, 
Middlesex, England. 
NEN Product, 549 Albany street, Boston, MA 02118, USA. 
P.O. Box 2435, Rivonia, 2128, RSA. 
21 McHardy Avenue, Port Elizabeth, RSA. 
Frankfurter Strasse 250, 0-6100, Darmstadt, Germany. 
LKB Biotechnology AB, Uppsala, Sweden. 
Madison, WI, 53711-5399, USA. 
P.O. Box 144, Muldersdrift, 1747, RSA. 
PO Box 14508, St Louis MO 63178, USA. 
P.O. Box 22400, Cleveland, Ohio, 44122, USA. 
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CHAPTER 3 
CLONING OF THE 915 REGION OF THE 16S 
rRNA GENE OF A STREPTOMYCIN 
RESISTANT M. TUBERCULOSIS ISOLATE 
3.1 INTRODUCTION 
The basic molecular biology techniques/methods used in this investigation are described in this 
chapter. The preparation of a recombinant plasmid for the sequencing of the streptomycin 
binding region of the 16S rRNA gene of a clinical isolate of M. tuberculosis resistant to 
streptomycin is described. The streptomycin binding region of the gene was amplified by the 
polymerase chain reaction and ligated into a T-tailed Smal site of pUC18. E. coli LK111 cells 
were transformed with this construct and selection was performed using the blue-white selection 
system on agar containing ampicillin (described in 3.2.6). 
3.2 METHODS 
3.2.1 PREPARATION OF MYCOBACTERIAL DNA 
A clinical isolate of M. tuberculosis (designated M.tbA) resistant to streptomycin, rifampicin, 
isoniazid, ethionamide, thiacetazone and cycloserine was obtained from the South African 
Institute of Medical Research, Cape Town. This was cultured on streptomycin-free Lowenstein 
and Jensen medium for approximately 4 months at 37°C in air prior to DNA extraction. DNA was 
extracted by a modification of the method described by van Soolingen et al (1991 ). A suspension 
of cells was prepared in 1.5 ml of TES buffer (10mM tris-HCI; 1mM EDTA; 150mM NaCl [pH 
8.5]) in 5ml Greiner tubes and heated to 75°C for 2 hours to ensure complete killing of all cells. 
(Experimentation done in this laboratory by Mr Bruce Allan showed that viable mycobacteria were 
still present if only 30 minutes were used for the heat killing. It was therefore decided to err on the 
side of caution because of the potential health hazard posed by the organism under 
investigation.) The killed cells were pelleted by centrifugation for 5 minutes at 3 OOOrpm in a 
Beckman GS-6 centrifuge, and resuspended in 500µ1 of TE buffer ( 1 OmM Tris-HCI, 1 mM EDTA 
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[pH 8.01). The cell suspension was transferred to a 1.5ml Eppendorf tube. A spatula-tip of 
lysozyme powder was added, mixed by vortexing, and the solution incubated at 37°C for 1 hour. 
Following this, 70µ1 of 10% SDS (w/v) and 6µ1 of proteinase K (1 Omg/ml) were added, mixed and 
incubated at 65°C for 1 O minutes. Thereafter, 80µ1 of N-cetyl-N,N,N-trimethyl ammonium bromide 
(cetramide) was added, mixed and incubated at 65°C for 10 minutes. Proteins and lipids were 
extracted by adding an equal volume of chloroform-isoamylalcohol (24:1 VN), the solution mixed, 
and the phases separated by centrifugation for 5 minutes at 14 OOOrpm in a microfuge 
(Eppendorf 5415). The DNA was precipitated by addition of a 0.6 volume of isopropanol to the 
supernatant fluid, the solution was mixed by inverting, and incubated at room temperature for 15 
minutes. The DNA was pelleted by centrifugation for 15 minutes at 14 OOOrpm in a microfuge. 
The supernatant fluid was discarded and excess salt removed by centrifugation of the pellet in 
1 ml 70% ethanol with the tube orientated in the opposite direction to that used to precipitate the 
DNA, such that the pellet migrated through the ethanol. The supernatant fluid was discarded and 
the pellet was dried under vacuum in a Servant speedivac concentrator, and finally dissolved in 
sterile, distilled water. 
3.2.2 PCR AMPLIFICATION OF A 336bp FRAGMENT OF THE 16S rRNA 
GENE 
Published mycobacterial 16$ rRNA sequences (Rogall et al, 1990) were used to design 19-mer 
oligonucleotide primers flanking the 915 region. These were synthesized by Professor D. Bates 
of the Department of Biochemistry, UCT. 
The DNA sequences of the primers used were 5'-AACGCATTAAGTACCCCGC-3' (forward, 
designated F2), and 5'-CTTGACGTCATCCCCACCT-3' (reverse, designated R1). These 
correspond to positions 863-882 and 1179-1198 of the 16SrRNA gene (E. coli numbering). 
A PCR reaction mix was prepared using buffer, nucleotides and Taq polymerase purchased from 
Boehringer Mannheim. The final 50µ1 mixture was composed as follows; 5µ1 of 10xbuffer, 1µ1 of 
1 OmM dATP, 1µ1 of 1 OmM dGTP, 1µ1 of 1 OmM dCTP, 1µ1 of 1 OmM dTTP, 0.25µ1 of Taq 
polymerase (1.25 units), 1µ1 of forward primer (11.86pmol/µI to give a final concentration of 
0.24µM), 1µ1 of reverse primer (9.99pmol/µI to give a final concentration of 0.2µM), 1 OµI of M.tbA 
mycobacterial DNA (approximately 400-600ng) and 29µ1 of water. 
PCR was performed on a JDI 8012 thermocycler using the following parameters: an initial 
temperature of 95°C for 7 minutes, followed by 30 cycles of; 95°C for 1 o seconds, 54°C for 30 
seconds and 70°C for 30 seconds. 
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A 1 OµI aliquot of the solution was then loaded onto a 3% agarose gel and subjected to 
electrophoresis (as described in 3.2.5), to confirm the amplification of a 336bp product and to 
estimate the concentration of DNA. 
3.2.3 LARGE SCALE PLASMID PREPARATION ('Maxiprep') 
The maxiprep method used is based on that of Greenaway and Dale (1983). 
Plasmids were prepared from and maintained in E.coli cells (DK1 or LK111). A single colony was 
picked from a Luria agar plate containing the appropriate antimicrobial agent (ampicillin or 
kanamycin) and inoculated into 5ml of Luria broth containing antibiotic. This was incubated at 
37°C, with shaking, for approximately 4 hours. 
A 4ml aliquot of the culture was added to 150ml prewarmed Luria broth containing antibiotic and 
incubated at 37°C overnight (approximately 18 hours) with shaking. Erlenmyer flasks (500ml) 
stoppered with cotton wool were used to ensure maximal aeration during the incubation. 
The cells were harvested by centrifugation at 5 ooorpm at 4°C for 20 minutes in a JA-10 rotor. 
The supernatant fluid was discarded. Cells were resuspended in 5ml of 25% sucrose in 0,05M 
Tris-HCI [pH 8.0] and transferred to a polypropelene centrifuge tube. 
To lyse the cells, a spatula-tip of dried lysozyme was added to the suspension, and mixed by 
intermittent swirling for 5 minutes. The suspension was kept on ice between times. Following this, 
5 ml of 0.25M EDTA [pH 8.0] was added, the solution was swirled intermittently, and replaced on 
ice. 
After 5 minutes, 8 ml of Triton/Doc solution (1 % Triton, 0.4% Sodium deoxycholate in 1 OmM Tris, 
1 mM Na2 EDTA [pH8.0]) was added rapidly from a 10ml pipette, and mixed by drawing up and 
expelling the solution three times. This was then left to stand on ice for approximately 20 to 30 
minutes. 
Plasmid DNA was separated from chromosomal DNA by pelleting the cell debris, and with it the 
attached chromosomal DNA, by centrifugation at 15 OOOrpm at 4°C for 45 minutes in a JA-20 
rotor. 
3.2.3.1 ISOPYCNIC GRADIENT CENTRIFUGATION 
Plasmid DNA was purified by isopycnic gradient centrifugation. Macromolecules, in this case 
DNA, are separated according to density in a solution of caesium chloride (CsCI) and ethidium 
bromide. 
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While pelleting the cell debris by centrifugation, the CsCI solution was prepared by weighing out 
9.5g of CsCI into a conical tube. On completion of the centrifugation, 10ml of the watery 
supernatant fluid (containing plasmid DNA), was added to the CsCI, and dissolved by gentle 
swirling. 
A 0.2ml aliquot of 1 Omg/ml ethidium bromide was added. 
The solution was transferred to polyallomer centrifugation tubes using a syringe to fill the tubes. 
The necks of the tubes were dried, and heat sealed. 
These were then loaded into a VTi65 ultracentrifuge and centrifugation at 50 000 rpm at 20°C 
was continued for 20 hours. 
Following centrifugation the separated DNA was visualised in a darkroom under ultraviolet light 
by virtue of the orange fluorescence produced by intercalated ethidium bromide. Two bands 
were visible; a distinct lower band corresponding to the covalently closed coiled plasmid DNA, 
and a less distinct higher band corresponding to chromosomal and/or nicked plasmid DNA. 
Plasmid DNA was eluted into plastic Greiner tubes by puncturing the polyallomer tube at the top 
and bottom and allowing drainage downward. The speed of flow was controlled by finger 
pressure on the upper puncture which allowed accurate collection of plasmid DNA while 
excluding the upper chromosomal DNA. 
3.2.3.2 REMOVAL OF ETHIDIUM BROMIDE AND CsCI 
Ethidium bromide was removed from the eluted plasmid DNA by adding an equal volume of 
isoamylalcohol, mixed by vortexing, and separation by centrifugation. The upper organic layer 
was discarded and the procedure repeated (usually twice more) until no pink colour was visible. 
To remove the CsCI, the plasmid preparation was dialysed overnight at 4°C against 500ml TE 
buffer (1 OmM Tris, 1 mM EDTA, [pH 8.0]). Three changes of buffer were made. 
The solution was removed from the dialysis bag, aliquotted into Eppendorf tubes, and the DNA 
precipitated by adding one-tenth volume of 4M LiCI and 2.5 volumes of absolute ethanol. This 
was left at -20°C overnight, followed by centrifugation at 14 OOOrpm for 15 minutes in a 
microfuge. The supernatant fluid was discarded, 70% ethanol was added and the tube 
centrifuged at 14 OOOrpm for 5 minutes in a microfuge. The supernatant fluid was discarded and 
the pellet dried under vacuum. The pellet was then resuspended in sterile, distilled water. The 
concentration and purity of the DNA was assessed by measuring absorbance of an aliquot of the 
solution at 260nm and 280nm. The absorbance at 260nm is directly proportional to the DNA 
concentration, and the ratio of absorbance 260nm:280nm allows an assessment of purity (the 
ratio 1.8 being uncontaminated DNA). 
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3.2.4 RESTRICTION ENZYME DIGESTION 
The pUC18 plasmid is designed to include a number of unique restriction sites in a multiple 
cloning site, as shown in Appendix A. Digestion of the plasmid using a restriction enzyme causes 
linearisation of the plasmid. This allows one to introduce compatible DNA fragments into this site 
by a ligation reaction. Restriction enzyme digestion can also be used to identify recombinant 
plasmids which on linearisation can be seen to be larger than the parent plasmid. Digestion can 
be performed to remove the insert from the parent plasmid which is recognised as a second 
band of DNA when visualised on agarose gel following electrophoresis. Restriction enzymes 
were used for each of these applications. 
Restriction enzyme digestion was performed according to the manufacturers recommendations. 
The reactions were terminated by adding one-tenth volume of a 10x stop buffer (50% glycerol, 
100mM Na2EDTA [pH8.0], 1% SOS, 0.1% bromophenol blue, 0.1% cyanol). 
3.2.5 AGAROSE GEL ELECTROPHORESIS 
DNA fragments were separated by electrophoresis in agarose gels of varying concentrations, 
chosen according to the size of the fragments to be separated. The concentration used varied 
from 0.8% to 3% agarose, with the lower concentration used for detecting the recombinant 
plasmids, and the higher concentration used for detecting the PCR fragments. 
Gels were prepared by dissolving appropriate amounts of agarose in TAE buffer (40mM Tris-
acetate, 1 mM EDT A) aided by heating the solution in a microwave oven. A 100µ1 aliquot of 
1 OOµg/ml ethidium bromide was added to 100ml of the agarose solution. The solution was 
allowed to cool to 56°C prior to being poured into perspex or plastic moulds, with a comb lowered 
into the molten agarose to form wells. Once the agarose had gelled it was placed in an 
electrophoresis tank with the gel covered by buffer. Aliquots of DNA were introduced into the 
preformed wells and electrophoresis performed at a constant voltage. 
After seperation the DNA was visualised in ultraviolet light on a UV illuminator. 
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3.2.6 PREPARATION OF VECTOR FOR LIGATION 
pUC18 contains a (3-lactamase gene which confers ampicillin resistance to cells which contain 
the plasmid. pUC18 also contains a portion of a (3-galactosidase gene into which a multiple 
cloning site has been engineered. The complementary portion of the beta-galactosidase gene is 
found in the genome of LK111. lsopropyl-(3-D-thiogalactopyranoside (IPTG) induces the lac 
operon causing the production of (3-galactosidase. This enzyme hydrolyses 5-bromo-4-chloro-3-
indolyl-(3-galactosidase (X-gal}, resulting in the production of bromochloroindole, a blue dye. 
This allows for the selection of transformed cells, as well as cells harbouring recombinant 
plasmids on agar containing ampicllin, IPTG and X-gal. Transformed cells will grow in the 
presence of ampicillin and produce the blue dye; therefore they are seen as blue colonies. 
However the (3-galactosidase gene is interrupted if extraneous DNA is introduced into the multiple 
cloning site, preventing the production of (3-galactosidase, and therefore colonies containing a 
recombinant plasmid will be white. 
One microgram of pUC18 was digested with Smal to produce a blunt-ended plasmid in a reaction 
mixture composed as follows; 5µ1 of pUC18 DNA, 1µ1 of Smal, 1µ1 of buffer A (Boehringer) and 
3µ1 of water. This was incubated at 37°C for 3 hours. 
3.2.6.1 CONSTRUCTION OF AT-TAILED VECTOR 
PCR amplification by Tag-polymerase causes the addition of a nucleotide (almost exclusively 
adenine) to the 3' end of the newly synthesized DNA (Clark, 1988). This causes inefficient ligation 
of the insert to blunt-ended plasmid DNA (Mole et al, 1989}. Therefore a method which improves 
the efficiency of ligation, the 'T-tailing' of the vector, was used (Marchuk et al, 1990). 
The entire 1 OµI of Smal digested pUC18 was used. To this 1µ1 of 1 OmM dTTP (final 
concentration of 0.5mM}, 5µ1 of 10x buffer (PCR buffer of Boehringer-Mannheim), 0.2µ1 Taq 
polymerase and 33.8µ1 of water were added. This 50µ1 reaction mix was incubated at 10°c for 2 
hours. The high temperature inactivates the Smal, while Taq polymerase catalyses the addition 
of a 3' thymidine. This produces a vector with a sticky-end complementary to PCR amplified 
DNA. 
The solution was extracted with phenol and chloroform-isoamylalcohol. A half volume of 
saturated phenol and a half volume of chloroform-isoamylalcohol (24:1 VIV) was added to the 
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supernatant fluid. The solution was mixed by vortexing, and the phases separated by 
centrifugation at 14 OOOrpm for 2 minutes in a microfuge. This step was repeated, followed by 
two extractions with a half volume of chloroform-isoamylalcohol (24:1 VN). The DNA was 
precipitated by adding one-tenth volume of LiCI and 2/2volumes of ice-cold absolute ethanol, 
mixed by inverting, and incubated at -20°C overnight. This was followed by centrifugation at 14 
OOOrpm for 15 minutes in a microfuge to pellet the DNA. The supernatant fluid was discarded and 
the pellet washed by the adding 1 ml of 70% ethanol and centrifugation at 14 ooorpm for 1 minute 
in a microfuge. 
The pellet was redissolved in 15µ1 of water. The DNA concentration was estimated roughly by 
agarose gel electrophoresis of 1µ1. The remaining 14µ1 was made up to 20µ1 with sterile, distilled 
water. 
3.2. 7 LIGATION REACTION 
Ligation of the 336bp fragment amplified from M.tbA into the T-tailed Smal site of pUC18 was 
done using plasmid and mycobacterial DNA in approximately 1 :1 molar ratios. A 20µ1 ligation 
reaction mixture was made up as follows; 1µ1 of the pUC18 solution (approximately 50ng DNA), 
2µ1 of PCR products containing the 336bp fragment to be inserted (approximately 5-10ng DNA), 
1µ1 of T4 DNA-ligase, 1µ1 of Smal, 2µ1 of 1 Ox ligase buffer and 13µ1 of water. 
The Smal was included to prevent recircularisation of pUC18. 
Ligation in the presence of Smal was compared to ligation not including Smal, which was run in 
tandem with the above experiment. The final 10µ1 solution contained; 1µ1 of pUC18, 2µ1 of the 
336bp fragment, 1µ1 of T4 DNA ligase, 1µ1 of 1 Ox ligase buffer and 5µ1 of water. 
These were incubated at 15°C overnight, following which the solutions were stored at 4°C. 
3.2.8 PREPARATION OF COMPETENT CELLS 
Competent DK1 cells were prepared by the following method for use in cloning experiments 
which did not require blue/white selection (not described). 
Luria broth (10ml) was inoculated with a colony of DK1 cells. This was incubated overnight 
(approximately 18 hours) at 37°C with aeration. A 0.5ml aliquot was removed and added to a 
500ml flask and incubated for approximately 4 hours (to reach an optical density of 0.5-0.6 at 
600nm). The culture was then cooled on ice, transferred to corex tubes and subjected to 
centrifugation at 4 OOOrpm at 4°C for 5 minutes in a YA-20 rotor. 
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The supernatant fluid was discarded and the cells in each corex tube resuspended in 3.25ml of 
60mM CaCI, 1 OmM Hepes [pH 7,2]. The cell suspensions were pooled into 2 tubes and 
incubated on ice for 20 minutes, prior to centrifugation at 4 OOOrpm at 4°C for 5 minutes. 
The supernatant fluid was discarded and the cells in each corex tube resuspended in 1.5ml of 
60mM CaCI, 10mM Hepes, 15% glycerol. 
The cells were divided into 1 OOµI aliquots and snap frozen for storage at -70°C. 
The competence of the cells was checked by transforming with circular closed plasmid and 
selection on Luria agar containing antibiotic. 
3.2.9 TRANSFORMATION OF E. coli LK111 CELLS. 
Previously prepared LK111 competent cells (efficiency estimated at 5x106/µg of DNA) stored in 
1 OOµI aliquots at -70°C were used. The cells were thawed on ice prior to the addition of the 
ligation mix. A 1 OµI aliquot of the ligation mix including Smal was used, while 5µ1 of the ligation 
mix without Smal was used. These volumes corresponded to an estimated 25ng of pUC18 DNA 
per transfomation reaction. The cells were mixed gently by swirling intermittently and kept on ice 
for 30 minutes. 
The cells were heat shocked at 42°C for precisely 2 minutes, then placed onto ice for 2 minutes. 
One milliliter of prewarmed Luria broth was added to the cells, and incubated at 37°C for 1 hour 
to allow expression of the ~-lactamase gene. 
Aliquots of 50µ1 of the cell suspension were then spread onto selective media; Luria agar plates 
containing ampicillin (50ng/µI), 2% X-gal in dimethyl formamide (250µ1/100ml), and IPTG 
(50µ1/100ml). After allowing for absorption of the liquid, the plates were inverted and incubated at 
37°C overnight. 
Transformed cells containing the M.tb fragment inserted into pUC18 were recognized as white 
colonies, because the ~-galactosidase gene was interrupted, amongst blue colonies. The blue 
colonies are those cells which contain pUC18, and are therefore resistant to ampicillin, but do not 
contain an insert to interrupt the ~-galactosidase gene. 
3.2.10 SMALL SCALE PLASMID PREPARATION ('Miniprep') 
To screen selected colonies for the presence of recombinant plasmid an alkaline lysis method of 
plasmid extraction based on that of Birnboim and Doly (1979) was used. 
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A single colony of transformed E. coli was inoculated into 10ml of Luria broth and incubated at 
37°C overnight (approximately 18 hours), while shaking. 
A 1.5ml Eppendorf tube was filled with culture broth followed by centrifugation at 14 OOOrpm for 
30s to 1 minute in a microfuge. The supernatant fluid was discarded and the cells resuspended 
in 90µ1 ofTris/EDTA/glucose (25mM Tris-HCI, 10mM EDTA, SOmM glucose [pH 8.0]). 
Cells were lysed by adding a spatula-tip of powdered lysozyme, and the mixture incubated at 
room temperature for 5 minutes. Thereafter, 200µ1 of freshly prepared NaOH/SDS solution (0.2N 
NaOH, 1 % SOS) was added, mixed by inverting, and incubated on ice for 5 minutes. 
To precipitate chromosomal DNA and protein, 150µ1 of ice cold 'high salt' (3M K, SM acetate) 
was added, mixed by vortexing, and incubated on ice for 15 minutes. The cellular debris and 
chromosomal DNA was pelleted by centrifugation at 14 OOOrpm for 5 minutes in a microfuge. 
The supernatant fluid was carefully removed and extracted with phenol and 
chloroform/isoamylalcohol. One-half volume of saturated phenol and 0.5 volume of 
chloroform/isoamylalcohol (24:1 VN) were added to the supernatant fluid, the solution was 
mixed thoroughly by vortexing, and the phases seperated by centrifugation at 14 OOOrpm for 2 
minutes in a microfuge. This step was repeated twice, but with 0.25 volume of phenol and 0.75 
volume of chloroform/isoamylalcohol. 
Plasmid DNA was precipitated by the addition of 0.6 volume of isopropanol. The solution was 
mixed by inversion, incubated at room temperature for 5 minutes, and the DNA pelleted by 
centrifugation at 14 OOOrpm for 15 minutes in a microfuge. (Alternatively the DNA was 
precipitated by adding 0.1 volume of 4M LiCI and 2.5 volumes of ice-cold 100% ethanol. This 
was incubated at -20°C overnight or at -70°C for 15 minutes prior to centrifugation.) 
The supernatant fluid was discarded and excess salt removed by centrifugation of the pellet in 
70% ethanol. 
The supernatant fluid was discarded and the pellet dried under vacuum. Finally the DNA pellet 
was dissolved in an appropriate volume of sterile. distilled water (usually 10-20µ1). 
3.2.11 SCREENING TRANSFORMANTS FOR RECOMBINANT PLASMIDS 
3.2.11.1 EcoRI LINEARISATION 
Ten white colonies were picked off of the selection medium and used to prepare plasmid DNA 
for digestion. EcoRI digested linear fragments were produced to screen for larger plasmids 
corresponding to the 336bp fragment ligated into pUC18. 
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The digestion mix consisted of 5µ1 of mini prep DNA, 1 µI of H buffer (Boehringer), 1 µI of EcoRI, 
1 µI of RNAse and 2µ1 of water. This was incubated at 37°C for 2% hours and then 
electrophoresed in a 0.8% agarose gel containing ethidium bromide to enable visualisation of the 
DNA under ultraviolet light. 
3.2.11.2 Hindlll/EcoRI DIGESTION 
Because the vector, pUC18, was T-tailed at the Smal site, the inserted fragment of DNA could 
not simply be cut out of the plasmid using Smal. Instead, two enzymes, which are known to have 
restriction sites on either side of the Smal site in the multiple-cloning site (see appendix A), were 
used to digest the clones. This produced two fragments, one approximately 2.8kb, and the other 
slightly larger than the original 336bp insert. 
The 20µ1 digestion mix was constituted as follows; 2µ1 of plasmid DNA (produced by miniprep), 
2µ1 of B buffer (Boehringer), 1 µI of EcoRI, 1 µI of Hind Ill, 1 µI of RNAse and 13µ1 of water. This 
was incubated at 37°C overnight before electrophoresis in a 0.8% agarose gel. 
3.3 RESULTS 
The mycobacterial DNA, produced by the method described, was seen as a compact band on 
0.8% agarose gel electrophoresis. No smearing of DNA, indicative of smaller sheared fragments, 
was seen. The DNA could be used for all the manipulations described in this chapter. The 
concentration of mycobacterial DNA produced by this method varied between preparations from 
24-990ng/µI. 
The polymerase chain reaction of M.tbA DNA successfully amplified a fragment of DNA of 
approximately 336bp. This was the size expected for the primers used. The fragment can be 
seen compared to a molecular weight marker in Figure 1. The solution was estimated to contain 
approximately 5-1 Ong/µI of the DNA fragment. 
The large scale plasmid DNA preparation gave a wide ranging yield; from 20µg to 350µg per 
maxiprep, with the average yield approximately 100µg. The DNA prepared was of a high quality 
with the 260nm/280nm ratios varying from 1.75 to 1.80. 
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The pUC18 plasmid, linearised by Smal and T-tailed as described in 3.2.6, was seen as a ±2.7kb 
fragment on a 0.8% agarose gel and the concentration estimated at approximately 50ng/µI (result 
not shown). 
The DK1 cells, prepared as described in 3.2.8, had an efficiecy of 1x108/µg DNA However these 
cells were not used for the selection of the cloned 915 region of M.tbA, as DK1 cells do not 
exhibit the blue/white selection which was required. 
The transformation of E. coli LK111 cells by the ligation mix which did not include Smal, resulted 
in the growth of 8 white colonies in a total of 233. Transformation of E. coli LK111 cells by the 
ligation mix which included Smat, gave 53 white colonies in a total of 164. This represents a 10 
times improvement in efficiency when Smal is included during the ligation reaction. (3% versus 
32% white of total colonies.) The presence of so many blue colonies despite the use of Sma I 
may be caused by conditions for ligation (the use of ligation buffer and low temperature) not 
being optimal for the activity of Sma I. 
Two of the ten colonies screened contained plasmids, which on linearisation by EcoRI digestion, 
were larger than control linearised pUC 18 (Figure 3.2). 
Each EcoRI/Hindlll digestion of plasmid DNA from the two selected colonies produced two 
fragments; one of approximately 2.7kb and one of approximately 336bp. These are shown in 
figure 3.2. 
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FIGURE 3.1: PCR amplified fragment of 16S rRNA gene from the streptomycin resistant M. 
tuberculosis isolate, M.tbA, seen on 3% agarose gel after electrophoresis. Lane 1: PCR amplified 
fragment. Lane 2: Boehringer Mannheim marker V (see appendix 8). 
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FIGURE 3.2: Two recombinant plasmids (designated pRIB1 and pRIB2) , digested by EcoRI or 
double digested by EcoRI and Hindi II , seen on 0.8% agarose gel after electrophoretic seperation. 
The linearised recombinant plasmids in lanes 2 and 4 can be seen to be larger than the parent 
plasmid, pUC18, in lane 6. Lanes 3 and 5 show a second band of DNA of ±336bp excised from 
the recombinants by the double digestion. 
Lane 1: Lambda Hindlll digested DNA. Lane 2: pRIB1 Hindi II digested DNA. Lane 3: pRIB1 
EcoRI and Hindlll digested DNA. Lane 4: pRIB2 Hindlll digested DNA. Lane 5: pRIB2 EcoRI and 
Hindlll digested DNA. Lane 6: pUC18 Smal linearised DNA. 
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CHAPTER4 
DNA SEQUENCING OF THE 915 REGION OF 
THE 16S rRNA GENE OF A STREPTOMYCIN 
RESISTANT M. TUBERCULOSIS ISOLATE 
4.1 SUMMARY 
The DNA sequence was determined for the 915 region of the 16S rRNA gene of a M. 
tuberculosis isolate, M.tbA. This organism is resistant to multiple antitubercular drugs, including 
streptomycin. Two recombinant plasmids, pRIB1 and pRIB2, were constructed as described in 
chapter 3. These contain a 336bp fragment of the 915 region of M.tbA inserted into the T-tailed 
Smal site of pUC18. The plasmids were extracted from transformed LK111 cells by a 
modification of the method of Bimboim and Daly (1979), and sequenced by the dideoxy-Sanger 
method (Sanger et al, 1975; Sanger et al, 1977). The DNA sequence was then compared to the 
equivalent published sequences of M. tubeculosis (Rogall et al, 1990) and E. coli and found to 
contain an A~G transition at position 913 (E. coli numbering). 
4.2 METHODS 
4.2.1 PLASMID EXTRACTION 
The method used to extract plasmid DNA for sequencing was modified from that described 
previously (chapter 3.2.10). The changes were made to improve the quantity and quality of DNA, 
as sequencing done on DNA prepared by the method described in 3.2.1 o did not give good 
quality results. 
The changes made were: 
1.) the entire 10ml culture was extracted to give as much template DNA as possible for the 
sequencing reaction; 
2.) larger volumes of solutions were used, i.e. 400µ1 of the NaOH/SDS solution, 300µ1 of the 
'high salt' solution; 
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3.) the purification steps differed in that the plasmid DNA in the supernatant fluid was 
precipitated and resuspended in TES (1 OmM Tris-HCI; 1 mM EDTA; 150mM NaCl [pH 8.51), prior 
to extraction with phenol and chloroform-isoamylalcohol; and finally, 
4.) the DNA pellet was dissolved in 30µ1 sterile, distilled water. 
A 2µ1 aliquot of the final solution was diluted in water and scanned in a Beckman DU-40 
spectrophotometer from 220-310nm to estimate the concentration and purity of the DNA. 
4.2.2 SEQUENCING REACTION 
Sequencing was performed using Sequenase Version 2.0 from United States Biochemicals. The 
method is based on the dideoxy-Sanger method (Sanger et al, 1975; Sanger et al, 1977). 
In this method a single strand of DNA (either M13 or denatured double-stranded plasmid DNA) is 
used as a template. An oligonucleotide primer is chosen which anneals to a known sequence of 
the template towards the 3' end of the area to be sequenced, and extension of the 
complementary strand of DNA is commenced. However the extension is terminated by the 
incorporation of nucleotide analogues (2', 3'-dideoxynuleoside 5'-triphosphates), which do not 
have the 3'-0H group needed for further chain elongation. Four separate reactions are 
performed; each reaction vessel contains all the constituents needed for DNA polymerisation, 
but also includes a terminating nucleotide analogue of one base type. Therefore, in each reaction 
the DNA strand is terminated at one of the four bases, resulting in multiple lengths of DNA which 
all terminate with the same base. The DNA is labelled by the inclusion of a radiolabelled 
nucleotide. The four completed reactions are then loaded onto a denaturing polyacrylamide gel, 
and the DNA strands are separated electrophoretically. DNA fragments differing in length by a 
single base or more will be separated. Autoradiography of the gel then allows reading of the 
sequence. The shorter chains migrate faster, therefore the sequence is read from bottom to top 
in the direction of elongation, i.e. 5' to 3'. 
Half of the plasmid DNA was used for the forward primer sequencing reaction and half for the 
reverse reaction. Using the modified method of plasmid extraction described above (4.2.1 ), up to 
50µg of DNA per reaction was used. The primer used for forward sequencing, 5'-
AACGCATTAAGTACCCCGC-3' (positions 863-882), was the same primer used for amplification 
of the insert (F2). The primer used for reverse sequencing, 5'-CGCGTTGCATCGAATTAAT-3', 
corresponds to a sequence 50bp downstream of the 915 region {positions 955-974, designated 
R2). 
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Denaturation. 
The double stranded plasmid DNA was denatured by the addition of 2µ1 of 2M NaOH to 8µ1 of 
the plasmid DNA (an estimated 28pmols; in sterile distilled water). This was incubated at 37°C 
for 30 minutes. 
Annealing and neutralisation. 
Two microliters of either primer (949pmols of F2 for the forward reaction, or 470pmols of R2 for 
the reverse reaction), 2µ1 of 1 M HCI, 2µ1 of reaction buffer and 4µ1 of water were added to give a 
final volume of 20µ1. This solution was incubated at 37°C for 30 minutes. 
The DNA was precipitated by the addition of 50µ1 of absolute ethanol, incubated on dry ice for 30 
minutes, and followed by centrifugation at 14 OOOrpm for 15 minutes in a microfuge. The pellet 
was washed in 70% ethanol and dried under vacuum. 
During this time the termination mixes were prepared by adding 2.5µ1 of each of the solutions 
containing ddCTP, ddATP, ddTTP, and ddGTP to individual Eppendorf tubes. These were 
incubated at 37°C until needed. 
Extension and Labelling. 
The DNA was redissolved in 8µ1 water, and 2µ1 of the reaction buffer was added, followed by the 
addition of 1.7µ1 dimethylsulphoxide (DMSO), 1 µI of 0.1 M dithiothreitol (OTT), 2µ1 of labelling 
mix (from a 1:15 dilution in water of the dGTP 5x concentrate to give a final concentration of 
55nM of each of dGTP, dCTP and dTTP), 1µ1 of 35s ([a.-35s]-dATP), and 2µ1 of sequenase 
(DNA polymerase diluted 1 :8 with the enzyme dilution buffer). 
Tennination. 
The solution was vortexed briefly and a 3.5µ1 aliquot immediately added to each of the 
prewarmed 2.5µ1 termination mixes. These were incubated at 37°C for 4 minutes prior to the 
addition of 4µ1 of stop buffer (95% formamide, 20mM EDTA, 0.05% bromophenol blue and 
0.05% xylene cyanol). 
These were stored at -20°C until polyacrylamide gel electrophoresis. 
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4.2.3 POL YACRYLAMIDE GEL ELECTROPHORESIS 
High resolution separation of DNA fragments was performed using 8% polyacrylamide gel 
electrophoresis. Denaturing conditions (8M urea). and the high running temperature of the gel 
prevented the formation of secondary structures within the DNA strands with resultant poor 
resolution. A buffer gradient was also used both to retard the movement of the faster migrating 
DNA strands and to improve resolution. 
Glass plates were prepared immediately before the pouring of the gel by a simple washing step 
using soap and water, followed by 70% ethanol, and finally acetone. The plates were not 
siliconised as no difficulty was encountered removing gels. 
The plates were apposed, separated by two 2mm spacers and 3mm Whatman number 1 filter 
paper. The plates used were of unequal length, resulting in an overhang by the longer plate. This 
is used to form the fourth side of the upper buffer tank during electrophoresis while allowing the 
gel to be bathed in buffer. 
Approximately 40 ml of 8% polyacrylamide in O.Sx NNB buffer (see reagents) was used per gel. 
A 140µ1 aliquot of freshly prepared 25% ammonium persulphate (AMPS) and 35µ1 of NNN'N'-
tetramethylethylenediamine (TEMED) was added and mixed briefly by swirling, to initiate 
polymerisation. 
The polyacrylamide solution was poured immediately, taking care to prevent bubbles from 
becoming trapped in the gel, as these distort the final DNA pattern. When filled to the top edge 
of the shorter plate a comb was inserted, blunt edge leading, to form a smooth surface. 
After polymerisation, the gel was used immediately or kept overnight sealed with Saran wrap. 
The comb was removed, and the gel clamped vertically against the electrophoretic apparatus 
with the shorter plate toward the upper buffer tank. Enough buffer was added to the upper tank to 
cover the upper surface of the gel, and 400ml added to the bottom tank. 
The gel was preheated by applying an electric field at constant power (30W) for 30 minutes. 
Samples were denatured at 100°c for at least 3 minutes before loading. The comb was then 
inserted between the plates at the top of the gel. This formed the wells. The wells were rinsed 
thoroughly with buffer to remove the highly concentrated urea which leaches out of the gel during 
the preheating step. If not well rinsed, the urea prevents the sample loaded from forming a sharp 
band, and results in poor resolution. 
The samples were loaded into the wells, 3µ1 per well, in the order CATGC. This order was always 
used when running sequencing gels. 
Electrophoresis was then performed at 40-45W for 1-1 Yz hours. When the leading blue marker 
was half way down the gel, 200ml of 3M sodium acetate was added to the bottom tank to create 
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a buffer gradient. The electrophoresis was continued until the leading blue marker reached the 
blotting paper at the bottom edge of the gel. 
The plates and gel were removed from the apparatus and the plates prised apart leaving the gel 
on the lower plate. The upper glass plate was removed, a sheet of Whatman 3MM paper was laid 
onto the gel and smoothed onto it carefully until the gel adhered to the paper. The paper and 
attached gel were then carefully peeled off of the bottom plate. This was laid onto a slab gel drier 
(with the paper below the gel), a film of saran wrap laid over the gel, and dried at 60°C under 
vacuum for 2-3 hours. 
Once dry, the gel was autoradiographed for 18 hours to 1 week, depending on the intensity of the 
bands. 
4.3 RESULTS 
The sequences of both clones (see Figures 4.1 and 4.2) were identical to each other but differed 
from published mycobacterial 16S rRNA sequences at a single position. A 913A-G transition 
was identified in both clones. 
38 
_. 
• .-"! 
:::: 
---
-
-
-
-
--
--
--
---.. 
-- --
-
--
- --
- --
--
-
-
- • 
-
-
C A T G C CAT G C C AT G C CA T. GC 
1 2 3 4 
FIGURE 4.1: Polyacrylamide sequencing gel of pRIB1 and pRIB2. This shows the 915 region 
of the 16S rRNA gene of M.tbA sequenced in both the forward (sequences 1 & 4) and 
reverse (sequences 2 & 3) directions. The 913A-tG transition is marked by an open arrow 
(¢ or ¢:,) in the forward sequences, and a closed arrow (-+ or +-) in the reverse sequences. 
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StrepR Mtb 
Streps Mtb 
E.coli 
StrepR Mtb 
Streps Mtb 
E.coli 
CTAACGCATTAAGTACCCCGCCTGGGGAGTACGGCCGCAAGGCT 
CTAACGCATTAAGTACCCCGCCTGGGGAGTACGGCCGCAAGGCT 
CTAACGCGTTAAGTCGACCGCCTGGGGAGTACGGCCGCAAGGTT 
******* ****** ************************* * 
913 
AAAACTCGAAGGAATTGACGGGGGCCCGCACAAGCGGCGGA 
AAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGCGGA 
AAAACTCAAATGAATTGACGGGGGCCCGCACAAGCGGTGGA 945 
******* ** ************************** *** 
905 
FIGURE 4.2: Sequence alignment of the streptomycin binding region of the 16S rRNA gene of 
the streptomycin resistant M. tuberculosis (StrepR Mtb) with the equivalent region of published 
M. tuberculosis (Streps Mtb) and E. coli. 
The numbers to the right of the sequences correspond to the position in the 16S rRNA gene of 
the nucleotide shown at the end of each row; the mycobacterial 16S rRNA gene is shorter than 
the E. coli gene. The A~G transition at position 913 is labelled and shown in bold. The 
sequences were aligned using the 'Clustal V' programme (Higgins et al, 1992); stars indicate 
base identity. 
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CHAPTER 5 
SCREENING STREPTOMYCIN RESISTANT 
M. TUBERCULOSIS ISOLATES BY THE 
AMPLIFICATION REFRACTORY MUTATION 
SYSTEM (ARMS) 
5.1 INTRODUCTION 
With the discovery of the 913A-j,G transition in an isolate of streptomycin resistant M. 
tuberculosis, we were interested in investigating the possibility that this mutation was present in 
other streptomycin resistant M. tuberculosis isolates. Forty isolates of streptomycin resistant M. 
tuberculosis were screened using the PCR based amplification refractory mutation system 
(ARMS) described by Newton et al, (1989). 
5.2 METHODS 
Isolates of M. tuberculosis were collected from the mycobacteria laboratory of Groote Schuur 
Hospital, and the Orange street laboratory of the South African Institute of Medical Research 
(SAIMR). All isolates were found to be resistant to streptomycin by the SAIMR. Aliquots of DNA 
from two streptomycin resistant M. tuberculosis isolates were kindly supplied by Ian Wiid of the 
Medical Biochemistry Department, Tygerberg. 
5.2.1 THE AMPLIFICATION REFRACTORY MUTATION SYSTEM 
To clone and sequence a large number of isolates is not a pratical means of detecting a single 
base mutation in a large number of isolates. The amplification refractory mutation system 
(ARMS) is a PCR based method of detecting single base changes. Two PCR reactions are 
performed simultaneously for each isolate screened. The 3' end of one of the primers 
corresponds to the base under investigation. It is this 3' end which differs in the two reactions; in 
one reaction the base at the 3' end of the primer is complementary to one of the possible bases 
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at the mutation position, while the other tube contains a primer whose 3' end is complementary 
to the alternate base (assuming there are only two possibilities). The method relies on the finding 
that a 3' mismatch in one of a set of primers effectively prevents amplification by PCR, while the 
simultaneous PCR reaction with the matched primer will amplify a fragment. Both of these 
results must be obtained for the test to be reliable, i.e. one positive and one negative. 
The two 18-mer forward primers were 5'-CCGCAAGGCT AAAACTCA-3' and 5'-
CCGCAAGGCT AAAACTCG-3'. The forward primers were labelled streps and strepR 
respectively. Each was used in combination with the same reverse primer, 5'-
TGACGTCATCCCCACCT-3' (R1). This was one of the primers used to PCR amplify the 336bp 
fragment used for cloning as described in chapter 3.2.2. 
5.2.1.1 OPTIMISATION 
Mycobacterial DNA was prepared by the method described in chapter 3.2.1. DNA from the 
streptomycin resistant isolate, M.tbA, and from a streptomycin sensitive isolate was used. 
The PCR mix incorporated dUTP and Uracil DNA glycosylase (UDG) in an effort to control 
contamination by previously generated fragments. This practice was later discontinued because 
the UDG was found to be incompletely inactivated at 95°C by Mr Bruce Allan (personal 
communication). 
PCR was performed using a JOI 8012 thermocycler using the following parameters; 37°C for 5 
minutes, 95°C for 5 minutes, followed by 40 cycles of; 95°C for 20 seconds, 56.3°C for 30 
seconds and 70°C for 30 seconds. 
A 1 OµI aliquot from each reaction was then loaded onto a 3% agarose gel for electrophoresis. 
5.2.1.1.1 Comparison of two annealing temperatures on specificity. 
PCR was performed on M.tbA using both strepR and streps forward primers in combination with 
a reverse primer (R1) in the format of an ARMS test. The template DNA was added at 120ng per 
reaction. Primer concentration was approximately 2.SµM of each. Two sets of identical reaction 
mixes were made. Thermal cycling was performed using the programme given in 5.2.1.1 for the 
first set of tubes, i.e. the annealing temperature was 56.3°C. During the thermal cycling of the 
second set, however, the annealing temperature was S0°C. 
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5.2.1.1.2 Comparison of two denaturation temperatures on sensitivity. 
ARMS was performed on M.tbA using strepR and streps forward primers in combination with a 
reverse primer (R1). The template DNA was added at 120ng per reaction. Primer concentration 
was 2.SµM of each. Two sets of identical reaction mixes were made. Thermal cycling was 
performed using the programme given in 5.2.1.1 for the first set of tubes. i.e. the denaturation 
temperature was 95°C. During the thermal cycling of the second set, however, the denaturation 
temperature was 96°C. 
5.2.1.1.3 Comparison of various concentrations of template DNA and two concentrations 
of primers. 
A dilution series of M.tbA (streptomycin resistant) DNA was made, and 1 OµI added to a PCR 
tube to give a final total of approximately 12pg, 120pg, 1.2ng, 12ng and 120ng of DNA per tube. 
Each of these was subject to PCR at two concentrations of primer. One reaction contained 
1 SOng (0.625µM) of each primer (strepR forward primer and R1 reverse primer), and the other 
600ng (2.SµM) of each primer. 
Simultaneously an experiment using a streptomycin sensitive M.tubercu/osis isolate and the 
streps forward primer was done. The concentration of primer was the same and template DNA 
concentration was approximately the same. viz. 1 Opg, 100pg, 1 ng, and 1 Ong. 
5.2.1.1.4 Comparison of DNA extraction methods. 
A simple method of extraction was sought for use during the screening of isolates in order to 
avoid the longer, more formal, 'cetramide' extraction method. 
Three simple methods were compared: 1) boiling in water for 5 minutes; 2) sonication in water 
for 10 minutes in a Branson 2000 sonicator; and 3) boiling and sonication. 
A loopful of M.tbA culture was scraped from a L&J slope, swirled in 200µ1 water in 3 Eppendorf 
tubes and sealed. Two of these were placed into boiling water for 5 minutes. On removal, one of 
the tubes was kept on ice, while the second tube along with the third tube was placed in the 
sonicator for 10 minutes. The three tubes were then spun in a microfuge at 14 OOOrpm for 30 
seconds to pellet the debris. 
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A 10µ1 aliquot of the supernatant fluid was used from each for PCR using the strepR-R1 primer 
combination. The PCR parameters were as before; 37°C for 5 minutes, 95°C for 5 minutes, 
followed by 40 cycles of; 95°C for 20 seconds, 56.3°C for 30 seconds and 70°C for 30 seconds. 
DNA extracted by the cetramide method was subject to the same PCR reaction, as was an 
aliquot of water, to serve as positive and negative controls respectively. 
Following PCR amplification, a 20µ1 aliquot was electrophoresed on a 3% agarose gel. 
5.2.1.2 ARMS SCREENING 
The routine used for ARMS screening was: 
1) extraction of DNA by boiling the culture in water, 
2) ARMS PCR using 1 OµI of supernatant fluid, 
3) electrophoresis of a 1 OµI aliquot on a 3% agarose gel with positive and negative controls. 
As a negative control 10µ1 of water was substituted for the 10µ1 of DNA. M.tbA was used as the 
positive control for the strepR-R1 combination. A positive control for the strepS-R1 primer 
combination was not always included on each run because the majority of test results were 
positive using these primers. However on occasions that a run did not include a positive result 
with these primers, the screen was repeated using DNA from one of the previously screened 
isolates known to give a positive result with these primers. 
5.3 RESULTS 
When comparing the two annealing temperatures, 50°C and 56.3°C, both sets of ARMS 
reactions produced identical results at both temperatures (figure 5.1). Both gave a positive result 
with the strepR-R1 primer combination, and a negative result with the strepS-R1 combination, as 
was expected for this 913 A~G mutant isolate. Because no false positive amplification occurred 
by the strepS-R1 primer combination at the lower annealing temperature the technique is highly 
specific. Thus lending a degree of confidence to the results. 
The fragment of DNA amplified by PCR using a higher denaturation temperature was seen on an 
agarose gel as a faint band (figure 5.1). It was not as distinct as that produced when using the 
lower denaturation temperature. The increase in denaturation temperature did not appear to 
improve sensitivity, but rather to decrease the sensitivity . 
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The lowest concentration of template DNA giving a visible product was found to be 
approximately 1 ng. This was seen in tubes in which 150ng of primer was used per reaction. The 
higher concentration of primer did not improve the sensitivity, on the contrary it caused the lower 
limit of detection to be approximately ten times higher. See figure 5.2. 
A PCR product was clearly visualised when using the boiling, as well as the boiling plus 
sonication methods (see figure 5.3). Sonication, per se, did not allow production of a distinct 
band, if any. 
The simple boiling of culture is adequate to release DNA into the water, and amplification by 
PCR of this DNA is possible. The addition of sonication does not improve the sensitivity 
appreciably. 
An example of a result obtained during the screening is shown in figure 5.4. The results of the 
entire screening are shown in table 5.1. 
Three isolates contained the 913A~G transition as screened for by ARMS. This represents 
<10% of the isolates screened; less than we had expected. In retrospect, the finding of the 
mutation in the first isolate sequenced (M.tbA), was perhaps very fortunate. 
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FIGURE 5.1: Agarose gel electrophoresis of ARMS done on M.tbA at two annealing 
temperatures and two denaturation temperatures. Lanes 1 & 2 denatured at 96°C, annealed at 
56.3°C. Lane 1: strepR-R1 of M.tbA. Lane 2: strepS-R1 of M.tbA. Lanes 3 & 4 annealed at 50°C, 
denatured at 95°C. Lane 3: strepR-R1 of M.tbA. Lane 4: strepS-R1 of M.tbA. Lanes 5 & 6 
annealed at 56.3°C, denatured at 95°C. Lane 5: strepR-R1 of M.tbA. Lane 6: strepS-R1 of M.tbA. 
Lane 7: marker V. 
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FIGURE 5.2: Agarose gel electrophoresis of PCR fragments generated by the primer pair 
,strepR-R1 , at various concentrations of template DNA (M.tbA), and two concentrations of primer 
(strepR-R1). Lane 1: marker V. Lanes 2-6: primer concentration 0.625µM. The amount of 
template is increased in each lane from left to right by a factor of 10. Lane 2: ±12 pg of M.tbA. 
Lane 3: ±120 pg of M.tbA. Lane 4: ±1.2 ng of M.tbA. Lane 5: ±12 ng of M.tbA. Lane 6: ±120 ng of 
M.tbA. Lanes 7-11: primer concentration 2.SµM, with the amount of template increased in each 
lane from left to right by a factor of 10. Lane 7: ±12 pg of M.tbA. Lane 8: ±120 pg of M.tbA. Lane 
9: ±1.2 ng of M.tbA. Lane 10: ±12 ng of M.tbA. Lane 11: ±120 ng of M.tbA. The lower primer 
concentration is seen to be ten times more sensitive. 
47 
1 2 3 4 5 6 
FIGURE 5.3: Agarose gel electrophoresis of PCR fragments generated by the primer pair 
strepR-R1 on DNA extracted from M.tbA by different methods. Lane 1: boiled M.tbA. Lane 2: 
boiled and sonicated M.tbA. Lane 3: sonicated M.tbA. Lane 4: negative control. Lane 5: positive 
control. Lane 6: marker V. 
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FIGURE 5.4: Agarose gel electrophoresis of ARMS screening of five isolates all giving a result 
indicative of the presence of the base adenine at position 913. Lane 1: marker V. Lane 2: 
positive control (M.tbA template, strepR-R1 primer pair). In lanes 3-14 the primer pairs alternate. 
i.e.strepR-R1 followed by strepS-R1. Lane 3 & 4: negative control. Lane 5 & 6: isolate number 
10. Lane 7 & 8: isolate number 15. Lane 9 & 1 O: isolate number 12. Lane 11 & 12: isolate 
number 6. Lane 13 & 14: isolate number 5. 
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TABLE 5.1: Results of the ARMS screening done on M.tbA and a further 40 streptomycin 
resistant M. tuberculosis isolates. 
ISOLATE ARMS RESULT 
1 (M.tbA) 913 A~G 
2 913 A~G 
3 913 A 
4 913 A 
5 913 A 
6 913 A 
7 913 A 
8 913 A 
9 913 A 
10 913 A 
11 913 A 
12 913 A 
13 913 A 
14 913 A 
15 913 A 
16 913 A 
17 913 A 
18 913 A 
19 913 A 
20 913 A 
21 913 A 
22 913 A 
23 913 A 
24 913 A 
25 913 A 
26 913 A 
27 913 A 
28 913 A 
29 913 A 
30 913 A 
31 913 A 
32 913 A 
33 913 A 
34 913 A 
35 913 A 
36 913 A 
37 913 A 
38 913 A 
39 913 A~G 
40 913 A 
41 913 A 
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CHAPTER 6 
DIRECT SEQUENCING OF 16S rRNA PCR 
AMPLIFIED FRAGMENTS FROM 
STREPTOMYCIN RESISTANT M. 
TUBERCULOSIS ISOLA TES 
6.1 INTRODUCTION 
Twenty-four of the isolates screened for the 913A-G transition were sequenced in the 915 
region. This was done, firstly; to confirm the results of the ARMS, and secondly; to determine 
whether any other mutations exist in this region of M. tuberculosis isolates resistant to 
streptomycin. The sequencing was done after amplifying the 915 region, using the polymerase 
chain reaction, and purifying the resulting linear double stranded DNA fragment, which was 
sequenced directly. This avoided the time consuming process of cloning as well as sequencing 
errors caused by Taq polymerase infidelities. 
6.2 METHODS 
6.2.1 PCR OF A 400bp FRAGMENT 
The upstream primer, 5'-GTAGTCCACGCCGTAAACG-3', (designated F1), was used in 
combination with the downstream primer, R1, described previously. 
The template DNA was extracted by simply boiling M. tuberculosis culture in 200µ1 of water, and 
using 1 OµI of the supernatant fluid for PCR. 
A 1 OµI aliquot of water was added to a PCR tube as a negative control. 
The PCR mix contained 150ng (±0.625µM) of each primer, the nucleotides dATP, dCTP, dGTP 
and dTTP, Taq polymerase and the appropriate buffer. 
Thermal cycling was done using the following progamme: 95°C for 5 minutes, followed by 40 
cycles of; 95°C for 10 seconds, 54°C for 30 seconds, 70°C for 30 seconds, and finally ending 
with a 5 minute chase at 70°C. An aliquot was loaded onto an agarose gel for electrophoresis to 
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check for the production of the correct sized fragment (400bp) and to estimate the concentration 
of DNA. 
6.2.2 PURIFICATION OF THE PCR PRODUCT 
Purification was performed using well to well elution, as described by Hansen et al (1992). This is 
a simple, quick method, with a good rate of recovery. 
6.2.2.1 WELL TO WELL ELUTION 
An agarose gel (3%) was poured placing two combs into the gel parallel to each other. Once the 
agarose had gelled, it was placed into an electrophoretic apparatus with the buffer not covering 
the gel as can be seen in figure 6.1. The PCR-amplified DNA solution was placed into the 
cathodal well and electrophoresis commenced. The progress of the band of DNA was monitored 
using a hand-held UV source. When the band was within 1-2mm of the anodal (retrieval) well, 
the electrophoresis was stopped. The buffer in the well was removed and replaced with a running 
buffer containing 10% 3M sodium acetate [pH6.0] and 10% sucrose in TAE. The electrophoresis 
was continued. The buffer caused the DNA band to become very sharp as it entered the well. 
This allowed most of the DNA to be removed in a small volume of buffer, and the fragment is 
separated from all other nucleic acids present in the PCR mix. The DNA was precipitated by 
adding 1 µI of glycogen and an equal volume of isopropanol. This was incubated at room 
temperature for 5 minutes and pelleted by cetrifugation at 14 OOOrpm in a microfuge. The DNA 
was then washed in 70% ethanol, dried, and redissolved in sterile, distilled water. 
The method was easy and quick, and produced DNA which could be sequenced nearly every 
time a sequencing reaction was performed. 
Sequencing after well to well elution was compared to sequencing after ammonium acetate 
precipitation. Two identical PCR reactions were performed. The DNA in one was precipitated 
using ammonium acetate. The DNA in the other was purified by well to well elution. These were 
then sequenced as described below, followed by denaturing PAGE and autoradiography. 
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FIGURE 6.1: Schematic diagram of well to well electrophoretic apparatus used for purifying PCR 
generated fragments. 
6.2.3 SEQUENCING 
The method used for sequencing the fragments produced by PCR differed somewhat from that 
used for sequencing of plasmid DNA The template was heat denatured (Casanova et al, 1990). 
Detergents were used to minimize reannealing of the template (Bachman et al, 1990). The 
annealing buffer was added to a frozen mixture of template, primer and detergent, to improve 
clarity of the sequencing gel (Andersen et al, 1992). A manganese buffer was used to enable 
reading of the sequence close to the primer. The ratio of primer to template was ±100:1, which 
has been shown to be a good ratio for direct sequencing (Casanova et al, 1990). 
Denaturing and annealing. 
The DNA template was dissolved in 9µ1 of water. A 1µ1 aliquot of primer F2 (±474pmoles), and 
2µ1 of the detergent mix (0.5% Tween 20 and 0.5% NP40 in a 1 :1 ratio) were added. This was 
heated at 100°C for 3 minutes before cooling at -70°C. Once the solution had solidified a 2µ1 
aliquot of annealing buffer was added. 
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Labelling reaction. 
Three microlitres of labelling buffer was added, 1µ1 of 35s-dATP, 2µ1 of T7 DNA polymerase 
(Pharmacia), 1.75µ1 of the detergent mix and 1µ1 of Mn2+ buffer (from Sequenase kit). This was 
mixed in a picofuge and incubated at room temperature for no longer than 2 minutes. 
Termination. 
A 2µ1 aliquot of each of the four dideoxynucleotide termination mixes was added to separate 
Eppendorf tubes, together with 0.5µ1 of the detergent mix per tube. 
The annealed and labelled DNA was then divided between the four tubes; 4.5µ1 per reaction tube. 
These were incubated at 40°C for 3 minutes, after which the reaction was stopped by the 
addition of 5µ1 of stop buffer per tube. 
The DNA was ready for PAGE immediately, or after storage at -20°C. 
6.2.4 POLYACRYLAMIDE GEL ELECTROPHORESIS 
The sequencing reaction was heated at 100°c for 3-5 minutes before loading onto an 8% 
polyacrylamide gel for electrophoresis and autoradiography in exactly the same way as described 
in chapter 4.2.3. 
6.3 RESULTS 
PCR amplification produced an estimated 500ng to 1.5µg (1.9-5. 7 pm oles) of DNA per reaction. 
Initially 5 tubes were combined for each sequencing reaction. However this was found to be 
unnecessary, as the DNA from a single PCR reaction produced sequencing gels of good quality. 
The well to well method of elution was found to be quick and easily performed. When compared 
to electroelution it was found that the amount of DNA recovered was very similar. (Result not 
shown.) 
Sequencing after DNA precipitation by ammonium acetate, without purification of the DNA 
template by well to well elution, gave a poor result when compared to well to well purification, as 
can be seen in figure 6.2. 
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The sequencing confirmed the ARMS results for the two isolates containing the 913 A~G 
transition, and for 22 isolates without the transition (Table 6.1). No other mutations were 
identified in this region. 
CATGC CATGC CAT GC 
1 2 3 
FIGURE 6.2: Autoradiograph of three sequencing reactions showing an example of the 913 A~ 
G transition (-+). Sequence 1 and 3 are the sequence of isolate number 3, comparing well to 
well elution (1) to simple precipitation (3). Sequence 2 is the sequence of isolate number 39 
which contains the 913 A->G transition(-+). 
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TABLE 6.1: Sequencing results for the 915 region of M.tbA and 24 further streptomycin resistant 
M. tuberculosis isolates. 
ISOLATE ARMS RESULT SEQUENCING 
1 (M.tbA) 913 A.-+G 913 A.-+G 
2 913 A.-+G 913 A.-+G 
3 913 A 913 A 
4 913 A 913 A 
5 913 A 913 A 
6 913 A 913 A 
7 913 A 913 A 
8 913 A 913 A 
9 913 A 913 A 
10 913 A 913 A 
11 913 A 913 A 
12 913 A 913 A 
13 913 A 913 A 
14 913 A 913 A 
15 913 A 913 A 
16 913 A 913 A 
18 913 A 913 A 
19 913 A 913 A 
20 913 A 913 A 
21 913 A 913 A 
22 913 A 913 A 
23 913 A 913 A 
24 913 A 913 A 
25 913 A 913 A 
39 913 A.-+G 913 A.-+G 
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CHAPTER 7 
CONCLUSIONS AND DISCUSSION 
Tuberculosis is a resurgent disease worldwide, with increasing levels of resistance to anti-
mycobacterial agents. 
We investigated one of the most important ribosomal sites of the streptomycin-ribosomal 
interaction in streptomycin resistant M. tuberculosis isolates using established methods of 
cloning and sequencing as well as the newer amplification refractory mutation system 
(ARMS) and direct sequencing of PCR fragments. 
We have shown; firstly, that a small proportion (3 of the 41 isolates screened) of the 
streptomycin resistant isolates contain a 913 A~G mutation in the 16S rRNA gene. 
Mutations in this region of M. tuberculosis had not been demonstrated previously. Secondly, 
the ARMS method is a sensitive, specific, quick and easy method for the detection of this 
mutation. 
Meier et al ( 1 994) confirmed our findings in one of the three streptomycin resistant isolates 
which they investigated. Interestingly, the same isolate also contained an S12 mutation at 
codon 88(Lys to Arg), emphasising the importance of excluding S12 mutations in these 
organisms. 
We have not proven that this mutation is a cause of streptomycin resistance in M. 
tuberculosis. This could be tested by introducing a gene mutated in the 913 position into M. 
smegmatis and measuring the streptomycin MIC (minimal inhibitory concentration). A 
significant increase in MIC would indicate that the single base mutation causes streptomycin 
resistance. 
The 913 A~G mutation occurs infrequently in streptomycin resistant M. tuberculosis 
isolates, while S12 mutations may occur more frequently, especially in multidrug-resitant 
isolates. It may be speculated, therefore, that the 913 A~G mutation and other rRNA 
mutations in highly conserved regions are found in organisms demonstrating primary 
resistance, while S12 mutations are found in organisms with secondary resistance. 
If a limited number of mutations are responsible for all streptomycin resistance in M. 
tuberculosis, and if these mutations are identified, the amplification refractory mutation 
system could be used as a revolutionary method of sensitivity testing. 
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APPENDIX B 
MOLECULAR WEIGHT MARKERS USED 
8.1 Lambda DNA digested with Hindlll. 
Fragment sizes (bp): 
23130 
9 416 
6 682 
4 361 
2 322 
2027 
564 
125 
8.2 Marker V (Boehringer Mannheim). 
Fragment sizes (bp): 
587 
540 
504 
458 
434 
267 
234 
213 
192 
184 
124 
123 
104 
89 
80 
64 
57 
51 
21 
18 
11 
8 
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